The number in a drug-test panel name does not guarantee a universal list of drugs. A “five-panel,” “ten-panel,” or “twelve-panel” test is shorthand for a set of drug categories or analytes, but different programs and laboratories may use different configurations.
This guide explains common panel designs and how to compare them. Explore individual substances in Substances and Drug Testing Panels.
What does “panel” mean?
A panel is the set of drugs, drug classes, metabolites, or validity markers included in an order or device. Some panel entries represent one analyte; others represent a class containing several reportable analytes. The number may count classes rather than every chemical that the laboratory measures.
A panel also does not describe the entire testing process. Two tests with the same analyte list can differ in specimen, screening technology, confirmation method, cutoffs, collection controls, laboratory certification, and medical review.
What is commonly included in a five-panel test?
A traditional five-category framework often includes:
- amphetamine-class drugs;
- cocaine metabolite;
- cannabis/THC metabolite;
- an opiate or opioid category; and
- phencyclidine (PCP).
This list is descriptive, not a universal specification. The federal workplace panel follows current HHS-authorized analytes and procedures. DOT-regulated testing uses the federal framework required by 49 CFR Part 40. A private nonregulated five-panel may use different opioid coverage or omit an analyte that another provider includes.
What is commonly included in a ten-panel test?
A ten-panel test often starts with a traditional five-panel concept and adds categories such as benzodiazepines, barbiturates, methadone, oxycodone, or other drugs. Which five are added varies widely. A retail cup, workplace laboratory panel, and clinical toxicology panel may all use “ten-panel” while testing different substances.
Ask for the analyte list rather than comparing price or panel count alone.
What is commonly included in a twelve-panel test?
Twelve-panel products often add further prescription or synthetic drugs, but there is no standard twelve-panel formula. Depending on the provider, added categories might include buprenorphine, oxycodone, methadone, MDMA-related analytes, or another drug. Fentanyl is not guaranteed and should be verified explicitly.
Expanded and custom panels
Expanded panels may include fentanyl, buprenorphine, tramadol, synthetic cannabinoids, ketamine, gabapentin, alcohol biomarkers, or locally relevant substances. Clinical laboratories can offer targeted definitive panels or custom orders.
More is not automatically better. An expanded panel can increase cost, create additional interpretation needs, and collect information unrelated to the stated purpose. Each analyte should have a legitimate reason, a validated method, a review pathway, and clear consequences defined before testing.
Why opioid coverage causes confusion
A basic “opiates” assay may focus on morphine-like compounds. It may not reliably detect fentanyl, buprenorphine, methadone, oxycodone, or other opioids unless they are ordered separately. Even when a panel says “opioids,” the individual analytes and sensitivity remain essential.
See Opioid and Fentanyl Drug Testing.
Specimen type changes the panel
Urine, oral fluid, hair, and blood do not necessarily use identical analytes or cutoffs. The best specimen depends on whether the purpose concerns recent exposure, a broader retrospective window, clinical management, regulated workplace compliance, or a forensic question.
A panel offered for urine cannot be assumed to have an equivalent oral-fluid version. Compare Drug Testing Methods.
Screen-only versus laboratory-confirmed panels
Point-of-care or at-home devices often provide rapid presumptive results. A laboratory-based program may include an initial screen followed by specific confirmation of non-negative findings. For decisions with employment, legal, treatment, or safety consequences, the confirmation and review plan is as important as the panel itself.
Read At-Home Drug Tests Versus Laboratory Tests.
How to compare panel specifications
| Question | Why it matters |
|---|---|
| Which analytes are listed by name? | Panel counts can hide major coverage differences. |
| Which specimen is used? | Specimens emphasize different detection periods and use cases. |
| What are the screening and confirmation cutoffs? | Cutoffs affect how results are classified. |
| Are non-negative results confirmed? | Specific confirmation reduces uncertainty from a class-based screen. |
| Does the panel include fentanyl and relevant prescriptions? | These are not guaranteed by a generic opioid or expanded label. |
| Who reviews legitimate medical explanations? | Medical review can change the final verified workplace result. |
| Which standards govern collection and laboratory work? | Regulated and nonregulated programs can have different requirements. |
Choosing a panel by purpose
Federal or DOT-regulated workplace testing
Use the currently required federal panel, specimen, forms, laboratory, and review procedures. A commercially marketed panel is not a substitute for regulatory compliance.
Nonregulated workplace testing
Align the panel with written policy, job risks, state law, contractual duties, and consistent administration. Review state restrictions and cannabis protections before implementation.
Clinical care
Order only tests that answer a clinical question. Consider prescribed drugs, relevant unexpected substances, method limitations, and how each possible result would affect care.
Home testing
Read the FDA-authorized or cleared product labeling, analyte list, cutoff information, and instructions. Treat a non-negative screen as preliminary and use the recommended laboratory confirmation route.
Key takeaway
Choose a drug-test panel by its analytes and procedures, not its number. Verify the specimen, cutoffs, confirmation, medical review, and governing rules before ordering or acting on a result.
Continue with Drug-Test Cutoff Levels and Drug-Test Method and Panel Comparison.
Sources
- SAMHSA: Workplace Drug Testing Resources and Authorized Panels
- SAMHSA: HHS Guidelines and Federal Forms
- U.S. Department of Transportation: 49 CFR Part 40
- FDA: Drugs of Abuse Tests
Last evidence review: October 29, 2026.